(LOS ANGELES) – September 22, 2023 - The Terasaki Institute for Biomedical Innovation (TIBI) welcomes Zhaohui Wang, Ph.D., as its new Assistant Professor and Director of Precision Medicine. His main research focus is on discovering innovative bioengineering solutions to combat cancer.
Along with a talented group of scientists, Dr. Wang helped to develop the micro-organosphere (MOS) technology, which effectively creates uniform micro-droplets containing tiny 3D tissue structures that mimic a patient's tumor. These micro-organospheres serve as models to use in screening and developing personalized therapeutic cancer treatments. As compared with traditional organoids, MOS technology offers faster and higher throughput, expanded experimental capabilities, and better retention of the heterogeneity and microenvironment of the original tumors.
Dr. Wang will soon join forces with other TIBI scientists to solve the biggest problems in the biomedical field. This includes finding treatments for the most difficult cancers, such as pediatric gliomas, prostate cancer, and even some rare cancers - those where progress is slowed by the lack of preclinical models.
By combining next-generation organoid technology, cutting-edge biomaterials, organ-on-a-chip, machine learning, and AI, the aim is to create highly advanced patient avatars that mimic the complexities of the immune system and tumor physiological conditions.
“We welcome Dr. Zhaohui Wang to our TIBI team and know he will be instrumental in maximizing the capabilities of the MOS technology,” said Dr. Ali Khademhosseini, TIBI’s Director and CEO. “It will prove to be a powerful partnership with the various existing technologies that we have at our laboratory.”